



Image

TFW 1646/Boxse

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/995,225
	Filing Date	November 26, 2001
	First Named Inventor	Ruoping CHEN, et al.
	Art Unit	1646
	Examiner Name	Unassigned
Total Number of Pages in This Submission	Attorney Docket Number	21.US18.CP

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s) Figs. #	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> <small>Seq</small> <small>uen</small> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Sequence Listing (33 pages);
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Sequence Listing Submission Statement; Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input checked="" type="checkbox"/> CD, Number of CD(s) <u>One (1)</u>	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Errors were located on the originally filed Sequence Listing. These errors have been corrected on the Sequence Listing and CD-R being filed herewith.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Arena Pharmaceuticals, Inc. Ann A. Wieczorek, J.D. Reg. No. 46,087
Signature	<i>AWieczorek</i>
Date	19-Dec-2003

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	C. M. McClure
Signature	<i>CM McClure</i>
Date	19-Dec-2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Our Ref. No.: 21.US18.CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:)
)
Inventors : **Ruoping CHEN, et al.**)
)
Serial No. : **09/995,225**) Art Unit : 1646
)
Filed : **November 26, 2001**) Examiner : Unassigned
)
Title : **ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF**)
HUMAN G PROTEIN COUPLED RECEPTORS)

SEQUENCE SUBMISSION STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


One (1) copy of the Sequence Listing in computer readable form on CD-ROM as required by 37 C.F.R. § 1.52(e), § 1.77(b)(4), § 1.821(e) and/or § 1.96(c) is submitted herewith, along with a paper copy (33 pages). An error was discovered in the originally filed Sequence Listing. This error has been corrected in the attached version of the Sequence Listing.

The machine format is IBM-PC, the operating system is MS-Windows, the file on the CD-ROM is entitled "Aren21.US18.CIP.revised.ST25" using PatentIn version 3.2. The size of the files is 53 KB.

As required by 37 C.F.R. § 1.821(f), the data on the disk is identical to the paper copy (113 pages) submitted herewith.

Respectfully submitted,

Dated: 19 Dec 2003

By: 
Ann A. Wiczorek, J.D.
Reg. No. 46,087
ARENA PHARMACEUTICALS, INC.
6166 Nancy Ridge Drive
San Diego, CA 92121-3223
(858) 453-7200